My Watchlist
Indicators
Local Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clarivate Plc Ordinary Shares (NY:CLVT)

3.890 +0.110 (+2.91%)
Official Closing Price Updated: 7:00 PM EDT, Oct 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clarivate Plc Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
12 Industrials Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Earnings Scheduled For February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
Preview: Clarivate's Earnings
 
Via Benzinga
12 Industrials Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
12 Industrials Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
12 Industrials Stocks Moving In Monday's After-Market Session
 
Via Benzinga
The Latest Analyst Ratings for Clarivate
 
Via Benzinga
Where Clarivate Stands With Analysts
 
Via Benzinga
Clarivate Buys Alethea, Creates Academia And Government Innovation Incubator
Clarivate PLC (NYSE: CLVT) disclosed the plan to create an Academia and Government Innovation Incubator to  
Via Benzinga
Clarivate Launches AI-Powered Tool For IP Forecasts And Budgets
Clarivate Plc (NYSE: CLVT) has launched Forecast, the next-generation artificial intelligence (AI)-driven solution designed to enable intellectual property (IP) professionals to efficiently  
Via Benzinga
Topics Artificial Intelligence Intellectual Property
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023
 
Via Benzinga
What 5 Analyst Ratings Have To Say About Clarivate
 
Via Benzinga
Where Clarivate Stands With Analysts
 
Via Benzinga
Analyst Expectations for Clarivate's Future
 
Via Benzinga
Adobe To Rally Over 12%? Here Are 10 Other Analyst Forecasts For Friday
B of A Securities cut the price target for DigitalOcean Holdings, Inc. (NYSE: DOCN) from $47 to $25. B of A Securities analyst Wamsi Mohan downgraded the stock from Buy to Underperform. DigitalOcean... 
Via Benzinga
Planet Labs PBC, GameStop And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures traded lower this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Generative AI Startup AI21 Labs Reaches Unicorn Status With Latest Funding Round
AI21 Labs, a front-runner in the AI domain specializing in large language models (LLMs), declared the completion of a $155 million Series C fundraiser.  
Via Benzinga
Topics Artificial Intelligence
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2023
 
Via Benzinga
The Latest Analyst Ratings for Clarivate
 
Via Benzinga
Goldman Sachs Reveals Long-Term AI Portfolio: Here Are The 50 Stocks To Monitor
 
Via Benzinga
Topics Artificial Intelligence
12 Industrials Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 7, 2023
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2023
 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 73 companies reached new 52-week lows. 
Via Benzinga
12 Industrials Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Clarivate Is Oversold Stock Brimming with Turnaround Potential, Analyst Predicts
Oppenheimer analyst Owen Lau initiates coverage on Clarivate Plc (NYSE: CLVT) with an Outperform rating and  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 13, 2023
 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 61 companies hit new 52-week lows. 
Via Benzinga
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.